Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMX-883 |
| Synonyms | |
| Therapy Description |
AMX-883 is a BRD9 degrader, which potentially induces differentiation of myeloid cells to inhibit tumor growth (Cancer Res (2026) 86 (8_Supplement): ND10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMX-883 | AMX883|AMX 883 | AMX-883 is a BRD9 degrader, which potentially induces differentiation of myeloid cells to inhibit tumor growth (Cancer Res (2026) 86 (8_Supplement): ND10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07723703 | Phase I | AMX-883 + Posaconazole AMX-883 | Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML (BRAMLIE) | Recruiting | USA | 0 |